Arsanis and X4 Pharmaceuticals Agree to Merger
November 27, 2018 07:00 ET
|
Arsanis, Inc.
– Merger Expected to Create NASDAQ-listed, Late-stage Biopharmaceutical Company Focused on Rare Diseases and Cancer – – Phase 3 Clinical Trial for X4P-001, a Novel CXCR4 Antagonist, Anticipated to...
Arsanis Reports Financial Results for Third Quarter 2018
November 09, 2018 08:00 ET
|
Arsanis, Inc.
WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb)...
Arsanis Reports Financial Results for Second Quarter 2018
August 13, 2018 08:00 ET
|
Arsanis, Inc.
WALTHAM, Mass. and VIENNA, Austria, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb)...
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
June 28, 2018 07:00 ET
|
Arsanis, Inc.
Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment and Evaluate Complete Clinical Trial DatasetArsanis to Continue Focus on Development of ASN500 for Prevention of RSV...
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
June 14, 2018 08:00 ET
|
Arsanis, Inc.
WALTHAM, Mass. and VIENNA, Austria, June 14, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies...
Arsanis Announces Pricing of Initial Public Offering
November 15, 2017 23:20 ET
|
Arsanis, Inc.
WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address...